JP2014502156A5 - - Google Patents

Download PDF

Info

Publication number
JP2014502156A5
JP2014502156A5 JP2013541211A JP2013541211A JP2014502156A5 JP 2014502156 A5 JP2014502156 A5 JP 2014502156A5 JP 2013541211 A JP2013541211 A JP 2013541211A JP 2013541211 A JP2013541211 A JP 2013541211A JP 2014502156 A5 JP2014502156 A5 JP 2014502156A5
Authority
JP
Japan
Prior art keywords
peptide
peptide according
isolated
vector
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013541211A
Other languages
English (en)
Japanese (ja)
Other versions
JP6069212B2 (ja
JP2014502156A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2011/050460 external-priority patent/WO2012072088A1/en
Publication of JP2014502156A publication Critical patent/JP2014502156A/ja
Publication of JP2014502156A5 publication Critical patent/JP2014502156A5/ja
Application granted granted Critical
Publication of JP6069212B2 publication Critical patent/JP6069212B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013541211A 2010-12-02 2011-12-02 ペプチド骨格設計 Expired - Fee Related JP6069212B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10193479 2010-12-02
EP10193479.2 2010-12-02
US201161475965P 2011-04-15 2011-04-15
US61/475,965 2011-04-15
PCT/DK2011/050460 WO2012072088A1 (en) 2010-12-02 2011-12-02 Peptide scaffold design

Publications (3)

Publication Number Publication Date
JP2014502156A JP2014502156A (ja) 2014-01-30
JP2014502156A5 true JP2014502156A5 (enExample) 2014-12-18
JP6069212B2 JP6069212B2 (ja) 2017-02-01

Family

ID=44022075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013541211A Expired - Fee Related JP6069212B2 (ja) 2010-12-02 2011-12-02 ペプチド骨格設計

Country Status (10)

Country Link
US (2) US9550811B2 (enExample)
EP (1) EP2646459B1 (enExample)
JP (1) JP6069212B2 (enExample)
CN (1) CN103282375B (enExample)
AU (1) AU2011335551B2 (enExample)
CA (1) CA2819416C (enExample)
EA (1) EA025152B1 (enExample)
NZ (1) NZ611176A (enExample)
WO (1) WO2012072088A1 (enExample)
ZA (1) ZA201304017B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013017488A2 (pt) 2011-01-06 2017-08-01 Bionor Immuno As peptídeos imunogênicos multiméricos e monoméricos
WO2013182662A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Vaccine
CA2874923C (en) 2012-06-06 2021-08-31 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
CN104436157A (zh) * 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
JP2016034944A (ja) * 2014-08-04 2016-03-17 日東電工株式会社 Ｃｔｌのアポトーシスを抑制するまたｃｔｌの誘導抑制を阻害するワクチン医薬組成物
EP3180352B8 (en) * 2014-08-17 2021-06-16 Cellivery Therapeutics Inc. Advanced macromolecule transduction domain (amtd) sequences for improvement of cell-permeability
US20160060311A1 (en) 2014-08-27 2016-03-03 Daewoong Jo Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Lung Cancer Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Lung Cancer Compositions Comprising the Same
CN107847544B (zh) * 2015-07-20 2021-10-15 小利兰·斯坦福大学董事会 用多聚体结合试剂检测细胞表型和定量
US20170029798A1 (en) 2015-07-27 2017-02-02 Cellivery Therapeutics, Inc. Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD)
WO2017026779A1 (en) 2015-08-10 2017-02-16 Cellivery Therapeutics, Inc. Improved cell-permeable cre (icp-cre) recombinant protein and use thereof
EP3334755B1 (en) 2015-08-10 2020-04-08 Cellivery Therapeutics, Inc. Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof
EP3337815B1 (en) 2015-08-18 2020-12-16 Cellivery Therapeutics, Inc. Cell-permeable (cp)- socs3 recombinant protein and uses thereof
RU2628690C2 (ru) * 2015-11-06 2017-08-21 Общество С Ограниченной Ответственностью 'Фарминтерпрайсез' Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
WO2018017442A1 (en) * 2016-07-18 2018-01-25 President And Fellows Of Harvard College Methods and compositions relating to covalently circularized nanodiscs
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812980D0 (en) * 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
CA3118412A1 (en) * 2018-11-02 2020-05-07 Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences Cell-penetrating peptide based on influenza virus m2 protein
CA3122200A1 (en) 2018-12-07 2020-06-11 Oxford University Innovation Limited Linkers
AU2023353862A1 (en) * 2022-09-30 2025-05-15 Capricor, Inc. Combination exosomal immunogenic compositions and methods
CN116077686B (zh) * 2022-12-15 2025-06-27 苏州智核生物医药科技有限公司 可酶切Linker及其用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE4209215A1 (de) 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh Hcv peptidantigene und verfahren zur bestimmung von hcv
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
EP2156845A1 (en) 1992-05-23 2010-02-24 GlaxoSmithKline Biologicals SA Combined vaccines comprising hepatitis B surface antigen and other antigens
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
ES2239819T3 (es) 1993-11-04 2005-10-01 Innogenetics N.V. Epitopos inmunodominantes de celulas t humanas del virus de la hepatitis c.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
ATE193893T1 (de) 1994-04-08 2000-06-15 Us Health Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t- lymphocyten und die diagnose des hcv-kontaktes
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
CN1330377C (zh) * 1996-03-10 2007-08-08 明治乳业株式会社 用于治疗变态反应疾病的基于肽的免疫治疗剂
ATE296313T1 (de) 1996-03-21 2005-06-15 Epimmune Inc Hla-a2.1 bindende peptide und deren verwendung
WO1997044469A2 (en) 1996-05-24 1997-11-27 Chiron Corporation Multiple epitope fusion protein
US6566330B1 (en) 1996-10-22 2003-05-20 Medical University Of South Carolina Foundation Research Development Positively charged non-natural amino acids, methods of making and using thereof in peptides
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
NO311807B1 (no) * 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
JP2003509465A (ja) 1999-07-19 2003-03-11 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｃ型肝炎ウイルスに対する細胞性免疫応答の誘導
US6258932B1 (en) 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
US20020076415A1 (en) 1999-12-14 2002-06-20 Jing-Hsiung Ou Hepatitis C virus gene products
GB0005703D0 (en) 2000-03-09 2000-05-03 Alpharma As Compounds
CA2421445A1 (en) 2000-09-01 2002-03-14 Epimmune Inc. Hla binding peptides and their uses
EP1195381A1 (de) 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
GB0026094D0 (en) 2000-10-25 2000-12-13 Imp College Innovations Ltd Methods
FR2824326B1 (fr) 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
AUPR593101A0 (en) 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
FR2839722A1 (fr) 2002-05-17 2003-11-21 Bio Merieux Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
ATE356385T1 (de) 2002-06-10 2007-03-15 Algonomics N V Verfahren zur vorhersage der bindungsaffinität der mhc-peptid-komplexe
EP1537418A2 (en) 2002-09-13 2005-06-08 Intercell AG Method for isolating hepatitis c virus peptides
ES2332590T3 (es) 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. Dimero peptidico.
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
EP1652858A1 (en) 2004-10-28 2006-05-03 Innogenetics N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
MX2007015105A (es) 2005-06-01 2008-03-18 Variation Biotechnologies Inc Formulacion de vacuna de influenza a base de peptido.
WO2008107400A1 (en) * 2007-03-02 2008-09-12 Genimmune N.V. Hcv polyepitope construct and uses thereof
CN101795705A (zh) 2007-05-31 2010-08-04 莱顿教学医院 皮内hpv肽接种
US8071540B2 (en) 2007-07-13 2011-12-06 University of Pittsburgh—of the Commonwealth System of Higher Education Virus derived antimicrobial peptides
US20100019186A1 (en) * 2008-07-25 2010-01-28 Eaton Corporation Engine valve assembly with valve can mountable to an engine cover
CN101412747B (zh) 2008-10-21 2011-04-20 中国药科大学 新型穿膜肽及其用途
US20110318830A1 (en) 2008-11-12 2011-12-29 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
WO2010081095A2 (en) * 2009-01-12 2010-07-15 The Regents Of The University Of California Methods and compositions for inhibiting hepatitis c virus replication

Similar Documents

Publication Publication Date Title
JP2014502156A5 (enExample)
van Riet et al. Mucosal IgA responses in influenza virus infections; thoughts for vaccine design
JP2014534202A5 (enExample)
JP2015524422A5 (enExample)
JP2015501840A5 (enExample)
JP2014503206A5 (enExample)
JP2015521206A5 (enExample)
JP2014530010A5 (enExample)
JP2016534034A5 (enExample)
JP2014507144A5 (ja) 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物
BR112013032723A2 (pt) antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
RU2019139064A (ru) Композиции и способы для лечения цитомегаловируса
JP2016506416A5 (enExample)
JP2012501959A5 (enExample)
JP2018148890A5 (enExample)
IL276210B2 (en) Mers-cov vaccine
RU2014135703A (ru) Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2, h2n2 и b
JP2014507146A5 (enExample)
JP2014509838A5 (enExample)
JP2012515557A5 (enExample)
JP2015506705A5 (enExample)
JP2014519817A5 (enExample)
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
EP2552490A4 (en) INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
RU2016108139A (ru) Композиция neisseria meningitidis и способ индуцирования иммунного ответа